Systems Pharmacology Approach for Prediction of Pulmonary and Systemic Pharmacokinetics and Receptor Occupancy of Inhaled Drugs

CPT: Pharmacometrics and Systems Pharmacology

Volumn 5, Issue 4, 2016, Pages 201-210

  Boger, E ^a,b   Evans, N ^b   Chappell, M ^b   Lundqvist, A ^a   Ewing, P ^a   Wigenborg, A ^a   Friden M ^a,c  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; BRONCHODILATING AGENT; FLUTICASONE;

ANIMAL EXPERIMENT; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SOLUBILITY; INHALATION; INHALATIONAL DRUG ADMINISTRATION; MUCOCILIARY CLEARANCE; NONHUMAN; PARTICLE SIZE; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; SYSTEMIC CIRCULATION; ANIMAL; ANIMAL MODEL; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; HUMAN; LUNG; MEDICINAL CHEMISTRY; METABOLISM;

ADMINISTRATION, INHALATION; ANIMALS; BIOLOGICAL AVAILABILITY; BRONCHODILATOR AGENTS; CHEMISTRY, PHARMACEUTICAL; FLUTICASONE; HUMANS; LUNG; MODELS, ANIMAL; MODELS, BIOLOGICAL; RATS; RECEPTORS, GLUCOCORTICOID;

EID: 84963864898     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12074     Document Type: Article

References (43)

1. Sanders, M., Inhalation therapy: An historical review. Prim. Care Respir. J. 16, 71-81 (2007).
2. Bäckman, P., Adelmann, H., Petersson, G., &, Jones, C.B., Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product. Clin. Pharmacol. Ther. 95, 509-520 (2014).
3. Olsson, B., et al,. Pulmonary Drug Metabolism, Clearance, and Absorption. Controlled Pulmonary Drug Delivery (eds., Smyth, H., &, Hickey, A.,) pp. 21-50 (Springer, New York, NY, 2011).
4. Winkler, J., Hochhaus, G., &, Derendorf, H., How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc. Am. Thorac. Soc. 1, 356-363 (2004).
5. Agu, R.U., Ugwoke, M.I., Armand, M., Kinget, R., &, Verbeke, N., The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2, 198-209 (2001).
6. Patton, J.S., Fishburn, C.S., &, Weers, J.G., The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 1, 338-344 (2004).
7. Cooper, A.E., Ferguson, D., &, Grime, K., Optimisation of DMPK by the inhaled route: challenges and approaches. Curr. Drug Metab. 13, 457-473 (2012).
8. Loira-Pastoriza, C., Todoroff, J., &, Vanbever, R., Delivery strategies for sustained drug release in the lungs. Adv. Drug Deliv. Rev. 75, 81-91 (2014).
9. Patton, J.S., &, Byron, P.R., Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 6, 67-74 (2007).
10. Forbes, B., et al,. Challenges in inhaled product development and opportunities for open innovation. Adv. Drug Deliv. Rev. 63, 69-87 (2011).
11. Boger, E., et al,. A novel in vivo receptor occupancy methodology for the glucocorticoid receptor: Toward an improved understanding of lung pharmacokinetic/pharmacodynamic relationships. J. Pharmacol. Exp. Ther. 353, 279-287 (2015).
12. Edsbäcker, S., Wollmer, P., Selroos, O., Borgström, L., Olsson, B., &, Ingelf, J., Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids? Pulm. Pharmacol. Ther. 21, 247-258 (2008).
13. Sakagami, M., In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug Deliv. Rev. 58, 1030-1060 (2006).
14. Sakagami, M., Kinoshita, W., Sakon, K., &, Makino, Y., Fractional contribution of lung, nasal and gastrointestinal absorption to the systemic level following nose-only aerosol exposure in rats: A case study of 3.7-micro m fluorescein aerosols. Arch. Toxicol. 77, 321-329 (2003).
15. Weber, B., &, Hochhaus, G., A pharmacokinetic simulation tool for inhaled corticosteroids. AAPS J. 15, 159-171 (2013).
16. Hochhaus, G., Möllmann, H., Derendorf, H., &, Gonzalez-Rothi, R.J., Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J. Clin. Pharmacol. 37, 881-892 (1997).
17. Chaudhuri, S.R., Lukacova, V., &, Woltosz, W.S., Simulating the disposition of budesonide from dry powder inhalers (DPIs) and nebulizer. < http://abstracts.aaps.org/Verify/aaps2013/postersubmissions/T3181.pdf > (2013).
18. Borghardt, J.M., Weber, B., Staab, A., &, Kloft, C., Pharmacometric models for characterizing the pharmacokinetics of orally inhaled drugs. AAPS J. 17, 853-870 (2015).
19. Gearhart, J.M., Jepson, G.W., Clewell, H.J. 3rd, Andersen, M.E., &, Conolly, R.B., Physiologically based pharmacokinetic and pharmacodynamic model for the inhibition of acetylcholinesterase by diisopropylfluorophosphate. Toxicol. Appl. Pharmacol. 106, 295-310 (1990).
20. Arundel, P.A., A multi-compartmental model generally applicable to physiologically-based pharmacokinetics. < https://www.researchgate.net/publication/267672776-A-multi-compartmental-model-generally-Applicable-To-physiologically-based-pharmacokinetics-Astra-Zeneca-UK > (1997).
21. Brown, R.P., Delp, M.D., Lindstedt, S.L., Rhomberg, L.R., &, Beliles, R.P., Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13, 407-484 (1997).
22. Campbell, J.L., Andersen, M.E., &, Clewell, H.J., A hybrid CFD-PBPK model for naphthalene in rat and human with IVIVE for nasal tissue metabolism and cross-species dosimetry. Inhal. Toxicol. 26, 333-344 (2014).
23. Chen, A., &, Kaufman, S., Splenic blood flow and fluid efflux from the intravascular space in the rat. J. Physiol. 490 (Pt 2), 493-499 (1996).
24. Peters, S.A., Physiological model for distribution. In Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations: Principles, Methods, and Applications in the Pharmaceutical Industry (ed., Peters, S.A.,) p. 111 (Wiley, Hoboken, NJ, 2012).
25. Lee, D., &, Wexler, A.S., Particle deposition in juvenile rat lungs: A model study. J. Aerosol Sci. 42, 567-579 (2011).
26. Anjilvel, S., &, Asgharian, B., A multiple-path model of particle deposition in the rat lung. Fundam. Appl. Toxicol. 28, 41-50 (1995).
27. Hofmann, W., Asgharian, B., Bergmann, R., Anjilvel, S., &, Miller, F.J., The effect of heterogeneity of lung structure on particle deposition in the rat lung. Toxicol. Sci. 53, 430-437 (2000).
28. Schmid, O., et al,. Model for the deposition of aerosol particles in the respiratory tract of the rat. I. Nonhygroscopic particle deposition. J. Aerosol Med. Pulm. Drug Deliv. 21, 291-307 (2008).
29. Pesic, J., et al,. In vivo assessment of mucociliary clearance in rodents via SPECT imaging after instillation and inhalation of a 99mTc-labelled colloid. American Thoracic Society International Conference Abstracts. Abstract #C37. COPD: What is new in imaging? A4327-A4327 (2014).
30. Creutzenberg, O., Muhle, H., &, Bellmann, B., Nasal retention and clearance of wood dust in rats. Ann. Occup. Hyg. 38 (Suppl), 895-901 (1994).
31. Yeh, H.C., Schum, G.M., &, Duggan, M.T., Anatomic models of the tracheobronchial and pulmonary regions of the rat. Anat. Rec. 195, 483-492 (1979).
32. Jones, J.H., &, Longworth, K.E., Gas exchange at rest and during exercise in mammals. In Treatise on Pulmonary Toxicology, Volume I: Comparative Biology of the Normal Lung (ed., Parent, R.A.,) pp. 271-307 (CRC Press, Boca Raton, FL, 1992).
33. Schreider, J.P., Nasal airway anatomy and inhalation deposition in experimental animals and people. In Nasal Tumors in Animals and Man (eds., Reznik, G., &, Stinson, S.F.,) pp. 1-26 (CRC Press, Boca Raton, FL, 1983).
34. Lansley, A.B., Mucociliary clearance and drug delivery via the respiratory tract. Adv. Drug Deliv. Rev. 11, 299-327 (1993).
35. Peters, S.A., Drug absorption and gut bioavailability. In Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations: Principles, Methods, and Applications in the Pharmaceutical Industry (ed., Peters, S.A.,) p. 47 (Wiley, Hoboken, NJ, 2012).
36. Brunner, E., &, Nernst, W., Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen. Hoppe Seylers Z. Physiol. Chem. 47, 56-102 (1904).
37. Noyes, A., &, Whitney, W.R., The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 19, 930-934 (1897).
38. Rodgers, T., &, Rowland, M., Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 95, 1238-1257 (2006).
39. Bäckström, E., et al,. Development of a novel lung slice methodology for profiling of inhaled compounds. J. Pharm. Sci.; e-pub ahead of print 2015.
40. Miller, A.H., Spencer, R.L., Stein, M., &, McEwen, B.S., Adrenal steroid receptor binding in spleen and thymus after stress or dexamethasone. Am. J. Physiol. 259 (3 Pt 1), E405-E412 (1990).
41. Spencer, R.L., Young, E.A., Choo, P.H., &, McEwen, B.S., Adrenal steroid type I and type II receptor binding: estimates of in vivo receptor number, occupancy, and activation with varying level of steroid. Brain Res. 514, 37-48 (1990).
42. Wadenberg, M.L., Kapur, S., Soliman, A., Jones, C., &, Vaccarino, F., Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150, 422-429 (2000).
43. Jones, H., &, Rowland-Yeo, K., Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst. Pharmacol. 2, e63 (2013).